GB9403250D0 - Therapeutic use of myelin-associated glycoprotein (mag) - Google Patents

Therapeutic use of myelin-associated glycoprotein (mag)

Info

Publication number
GB9403250D0
GB9403250D0 GB9403250A GB9403250A GB9403250D0 GB 9403250 D0 GB9403250 D0 GB 9403250D0 GB 9403250 A GB9403250 A GB 9403250A GB 9403250 A GB9403250 A GB 9403250A GB 9403250 D0 GB9403250 D0 GB 9403250D0
Authority
GB
United Kingdom
Prior art keywords
myelin
mag
therapeutic use
associated glycoprotein
glycoprotein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB9403250A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McGill University
Original Assignee
McGill University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by McGill University filed Critical McGill University
Priority to GB9403250A priority Critical patent/GB9403250D0/en
Publication of GB9403250D0 publication Critical patent/GB9403250D0/en
Priority to AU17035/95A priority patent/AU1703595A/en
Priority to PCT/CA1995/000089 priority patent/WO1995022344A1/en
Priority to CA 2183630 priority patent/CA2183630A1/en
Priority to SE9703032A priority patent/SE9703032D0/en
Pending legal-status Critical Current

Links

GB9403250A 1994-02-21 1994-02-21 Therapeutic use of myelin-associated glycoprotein (mag) Pending GB9403250D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB9403250A GB9403250D0 (en) 1994-02-21 1994-02-21 Therapeutic use of myelin-associated glycoprotein (mag)
AU17035/95A AU1703595A (en) 1994-02-21 1995-02-17 Therapeutic use of myelin-associated glycoprotein (mag)
PCT/CA1995/000089 WO1995022344A1 (en) 1994-02-21 1995-02-17 Therapeutic use of myelin-associated glycoprotein (mag)
CA 2183630 CA2183630A1 (en) 1994-02-21 1995-02-17 Therapeutic use of myelin-associated glycoprotein (mag)
SE9703032A SE9703032D0 (en) 1994-02-21 1997-08-21 Therapeutic use of myelin-associated glycoportein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9403250A GB9403250D0 (en) 1994-02-21 1994-02-21 Therapeutic use of myelin-associated glycoprotein (mag)

Publications (1)

Publication Number Publication Date
GB9403250D0 true GB9403250D0 (en) 1994-04-13

Family

ID=10750657

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9403250A Pending GB9403250D0 (en) 1994-02-21 1994-02-21 Therapeutic use of myelin-associated glycoprotein (mag)

Country Status (5)

Country Link
AU (1) AU1703595A (en)
CA (1) CA2183630A1 (en)
GB (1) GB9403250D0 (en)
SE (1) SE9703032D0 (en)
WO (1) WO1995022344A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225691A1 (en) * 1995-06-27 1997-01-16 Research Foundation Of Cuny, Hunter College Compositions and methods using myelin-associated glycoprotein (mag) and inhibitors thereof
CA2190418A1 (en) * 1996-11-15 1998-05-15 Zhi-Cheng Xiao Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof
AU3134799A (en) * 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
JP2003532618A (en) * 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド Cells, nervous system-specific antigens and their uses
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
AU2001284865A1 (en) 2000-08-14 2002-02-25 Joan M. Fallon Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
GB0306309D0 (en) * 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
KR20170005191A (en) 2009-01-06 2017-01-11 큐어론 엘엘씨 Compositions and methods for the treatment or the prevention oral infections by e. coli
GB2480772B (en) 2009-01-06 2013-10-16 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US8974782B2 (en) 2011-02-07 2015-03-10 Glaxo Group Limited Treatment of stroke comprising anti-MAG antibodies
MX347770B (en) 2011-04-21 2017-05-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders.
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1721092A1 (en) * 1990-02-26 1992-03-23 Институт Цитологии Ан Ссср Strain of hydride cultured mammalian cells mus musculus l - a producer of monoclonal antibody to brain myelin glycoproteine, inhibiting activity of natural human killers

Also Published As

Publication number Publication date
CA2183630A1 (en) 1995-08-24
SE9703032D0 (en) 1997-08-21
WO1995022344A1 (en) 1995-08-24
AU1703595A (en) 1995-09-04

Similar Documents

Publication Publication Date Title
GB9403250D0 (en) Therapeutic use of myelin-associated glycoprotein (mag)
GB9417956D0 (en) Therapeutic agents
GB9418545D0 (en) Therapeutic agents
GB9415997D0 (en) Therapeutic agents
GB9417310D0 (en) Therapeutic agents
GB9416189D0 (en) Therapeutic agents
GB9420168D0 (en) Therapeutic agents
GB9416162D0 (en) Therapeutic agents
GB9402641D0 (en) Therapeutic agents
GB9410031D0 (en) Therapeutic agents
GB9411955D0 (en) Therapeutic agents
GB9409264D0 (en) Therapeutic agents
GB9415575D0 (en) Therapeutic agents
GB9401879D0 (en) Therapeutic agents
GB9420172D0 (en) Therapeutic agents
GB9403639D0 (en) Therapeutic agents
GB9415553D0 (en) Therapeutic agents
GB9419894D0 (en) Therapeutic agents
GB9415910D0 (en) Therapeutic agents
GB9415805D0 (en) Therapeutic agents
GB9415745D0 (en) Therapeutic agents
GB9415576D0 (en) Therapeutic agents
GB9416161D0 (en) Therapeutic agents
GB9415556D0 (en) Therapeutic agents
GB9416427D0 (en) Therapeutic agents